# US 2013/0296184 A1 · Novel Method for Diagnosing Lyme Disease Using a Cellular Immunological Test

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296184 A1
- Document ID: US20130296184A1
- Status: Published application
- Kind: A1
- Application number: 13/824,321
- Filed: 2011-09-21
- Published: 2013-11-07
- Earliest claimed: 2010-09-21
- Assignees: Stichting Katholieke Universiteit
- Inventors: Leonardus Antonius Bernardus Joosten; Mihai Gheorghe Netea; Johannes Willem Maarten van der Meer; Bart Julian Kullberg
- Web page: https://patentgrep.com/patent/US20130296184A1

## CPC

- G01N 33/6866: {Interferon}
- G01N 33/56911: {Bacteria}
- G01N 33/6869: {Interleukin}
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of Borrelia antigens and (c) determining the expression level of a pro-inflammatory cytokine in said sample at the end of step (b).

## Claims

### Claim 1

A method for diagnosing Lyme disease in a subject, the method comprising the steps of:
(a) contacting a sample obtained from said subject with a source of Borrelia antigens;
(b) determining the expression level of a pro-inflammatory cytokine in said sample at the end of step (a); and
(c) diagnosing Lyme disease in said subject when a detectable expression level or an increase of the expression level of a pro-inflammatory cytokine is determined in step (b).

### Claim 2 (depends on 1)

A method according to claim 1, wherein the pro-inflammatory cytokine is selected from the group consisting of: IL-1β, IFNγ, IL-6 and IL-17.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

A method according to claim 1, wherein the expression level of a pro-inflammatory cytokine is determined by directly quantifying the amount of said pro-inflammatory cytokine and/or indirectly by quantifying the amount of a nucleotide sequence encoding said pro-inflammatory cytokine.

### Claim 5 (depends on 1)

A method according to claim 1, wherein said source of Borrelia antigen is a whole Borrelia cell.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the sample is a fluid obtained from the subject.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the fluid is selected from: blood, spinal cord fluid, or synovial fluid.

### Claim 8 (depends on 1)

A method according to claim 1, wherein in step (b) the Borrelia antigen is from a species of Borrelia selected from: B. burgdorferi, B. garinii and B. afzelii.

### Claim 9 (depends on 1)

A method according to claim 1, wherein in step (b) if several species of Borrelia are used as a source of Borrelia antigens, the sample of step (a) is divided into several sub-samples, each sub-sample being contacted with a source of antigens from one species of Borrelia.

### Claim 10

An assay device for diagnosing Lyme disease in a subject, wherein the device comprises a molecule which specifically binds a pro-inflammatory cytokine.

### Claim 11 (depends on 10)

A device according to claim 10, wherein the molecule which specifically binds a pro-inflammatory cytokine is an antibody.

### Claim 12 (depends on 10)

A device according to claim 10, wherein the device is a lateral flow test strip.

### Claim 13

A kit of parts for diagnosing Lyme disease in a subject comprising a) a source of Borrelia antigens and b) reagents for detecting the expression level of a pro-inflammatory cytokine.

### Claim 14 (depends on 13)

A kit according to claim 13, wherein the molecule which specifically binds a pro-inflammatory cytokine is an antibody.

### Claim 15 (depends on 5)

A method according to claim 5, wherein the Borrelia cell is heat-inactivated or formalin-fixated.
